Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of setidegrasib versus docetaxel in previously treated KRAS G12D-mutant advanced non-small cell lung cancer
CTR20262991Phase 3Active
- Sponsor
- Astellas Pharma
- Start
- Aug 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of setidegrasib in non-small cell lung cancer (NSCLC), sponsored by Astellas Pharma. Started Aug 2026; status: active.
02
Drugs
setidegrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262991.